Current Wegovy injection safety guide

Wegovy injection side effects: current rates and warning signs

Review common Wegovy injection side effects, current adult trial rates, serious warning signs, hydration and glucose questions, and compounded-semaglutide distinctions.

Educational guideUpdated August 9, 2026

A label-first Wegovy injection side-effect check

Confirm the exact product and route: FDA-approved Wegovy injection, Wegovy tablets, another branded semaglutide product, or a patient-specific compounded preparation.

Describe each symptom, when it began, severity, recurrence, food and fluid intake, urine output, glucose readings when relevant, and any refill or clinician-directed treatment change.

Separate common digestive or general symptoms from severe abdominal pain, dehydration, low blood sugar, vision, gallbladder, allergy, thyroid, or procedure warning signs.

Share insulin, sulfonylureas, kidney or eye history, severe stomach-emptying symptoms, pregnancy plans, oral medicines, and upcoming anesthesia or deep sedation.

Contact the responsible prescriber before skipping, repeating, stopping, restarting, or changing treatment; use urgent care for serious warning signs.

Direct answer

The current Wegovy label reports nausea, diarrhea, vomiting, constipation, abdominal pain, headache, and fatigue among common reactions in adults receiving the 2.4 mg once-weekly injection for weight reduction. In pooled adult trials, nausea occurred in 44% of Wegovy injection participants versus 16% receiving placebo; diarrhea occurred in 30% versus 16%, and vomiting in 24% versus 6%. These are product-, route-, dose-, and study-specific rates—not a forecast for one patient, Wegovy tablets, Ozempic, or compounded semaglutide. Contact the prescriber for persistent, worsening, recurrent, or treatment-limiting symptoms. Severe or persistent abdominal pain, repeated vomiting or inability to keep fluids down, markedly reduced urination, fainting or confusion, jaundice, sudden vision change, facial or throat swelling, trouble breathing, or a neck mass with swallowing difficulty needs prompt in-person or emergency assessment.

Common adverse reactions

Current Wegovy injection trials report route- and study-specific rates

The Novo Nordisk Wegovy prescribing information updated June 18, 2026 includes tablets and injection presentations. Table 3 pools adult weight-reduction trials of the 2.4 mg once-weekly injection. Nausea occurred in 44% of Wegovy injection participants versus 16% receiving placebo. The corresponding rates were 30% versus 16% for diarrhea, 24% versus 6% for vomiting, 24% versus 11% for constipation, 20% versus 10% for grouped abdominal pain, 14% versus 10% for headache, and 11% versus 5% for grouped fatigue. These comparisons describe trial groups and do not prove the cause, severity, or expected duration of one person’s symptom.

Keep each percentage tied to pooled adult weight-reduction trials of the branded 2.4 mg once-weekly Wegovy injection.
The abdominal-pain and fatigue rows group related terms, so they are not rates for one exact symptom presentation or severity.
Do not add percentages, present them as personal odds, or transfer them to adolescents, Wegovy tablets, Ozempic, another dose or indication, or compounded semaglutide.

Other reactions in the adult table

Indigestion, dizziness, bloating, burping, gas, reflux, hair loss, and local reactions also need context

The same adult injection table reports indigestion in 9% versus 3% with placebo, dizziness in 8% versus 4%, abdominal distension in 7% versus 5%, burping in 7% versus less than 1%, gas in 6% versus 4%, gastroesophageal reflux disease in 5% versus 3%, gastritis in 4% versus 1%, and hair loss in 3% versus 1%. A separate label section reports grouped injection-site reactions in 1.4% of Wegovy-treated adults versus 1% receiving placebo. That local category includes itching, redness, inflammation, firmness, and irritation; it is not a rate for any one symptom.

Report symptoms that are persistent, recurrent, worsening, severe, intake-limiting, or disruptive even when they appear in a common-reaction table.
A separate Wegovy injection-site-reaction guide addresses localized symptoms; spreading redness, pus, fever, severe pain, blistering, darkening, numbness, or skin breakdown needs prompt assessment.
Stronger side effects do not prove greater potency, absorption, or weight loss, and absence of symptoms does not prove the product is ineffective.

Digestive effects, hydration, and glucose

A common symptom still needs review when it is severe or affects intake

Current Wegovy labeling warns about acute kidney injury due to volume depletion and severe gastrointestinal adverse reactions, and it says Wegovy is not recommended in patients with severe gastroparesis. Low-blood-sugar risk can increase when semaglutide is used with insulin or an insulin secretagogue such as a sulfonylurea. The adult table’s 6% hypoglycemia figure applies to a defined subgroup with type 2 diabetes not using concomitant insulin and should not be treated as a universal rate. Symptoms, fluid intake, urine output, glucose context, other medicines, and medical history matter more than a copied percentage.

Record vomiting or diarrhea episodes, bowel pattern, ability to keep fluids and food down, urine amount and color, dizziness, fainting, weakness, and recent illness or heat exposure.
If glucose monitoring is part of care, record readings with symptoms, meals, activity, alcohol, insulin, sulfonylureas, and other glucose-lowering medicines.
Do not improvise a treatment hold, catch-up injection, restart, anti-nausea medicine, laxative, hydration recipe, or glucose plan from generic online advice.

Serious label warnings

Common stomach symptoms should not obscure abdominal, allergy, eye, thyroid, or procedure warning signs

The current label includes a boxed warning about thyroid C-cell tumors observed in rodents; it is unknown whether Wegovy causes these tumors in humans. Wegovy is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2. Label warnings also address acute pancreatitis, gallbladder disease, serious hypersensitivity, diabetic-retinopathy complications in patients with type 2 diabetes, increased heart rate, and pulmonary aspiration during general anesthesia or deep sedation. A page cannot diagnose these conditions or replace an examination.

Seek prompt care for severe or persistent abdominal pain, especially pain that may spread to the back, with or without vomiting; jaundice, fever, or right-upper-abdominal pain also needs assessment.
Trouble breathing or swallowing, facial or throat swelling, fainting, widespread hives, sudden vision change, a neck mass, persistent hoarseness, or rapidly developing serious symptoms requires urgent or emergency evaluation.
Tell the procedure and anesthesia team about the exact product, route, symptoms, and treatment timing; do not create a self-directed hold or restart schedule.

Route and product identity

Wegovy injection rates do not automatically apply to tablets, Ozempic, or compounded semaglutide

The current manufacturer label includes both Wegovy injection and once-daily Wegovy tablets, with route-specific routines, evidence, and indication details. The percentages on this page come from the adult 2.4 mg injection table. Ozempic also contains semaglutide but has distinct labels, indications, study populations, and adverse-reaction tables. A patient-specific compounded semaglutide preparation is not FDA-approved Wegovy, Ozempic, or an FDA-approved generic finished drug product and may differ in concentration, inactive ingredients, container, supplies, storage, and beyond-use date.

Preserve the product name, route, presentation, prescription and pharmacy label, manufacturer or dispensing pharmacy, refill or lot details, storage history, and a photo of the current package.
Do not transfer Wegovy injection percentages or presentation instructions to tablets, Ozempic, a compounded vial, a research-use product, or an unlabeled injection.
Avoid counterfeit or no-prescription sellers, copied injection charts, unverified additives, and claims that a compounded product is FDA-approved Wegovy or generic Wegovy.

Patient safety checklist

Questions to ask about possible Wegovy injection side effects

These points are educational and do not replace medical advice. A licensed clinician should review individual history, medications, risks, and state-specific availability before treatment.

✓

Is the product FDA-approved Wegovy injection, Wegovy tablets, another branded semaglutide product, or a patient-specific compounded prescription?

✓

Which symptoms occurred, when did they begin, how severe are they, and are they stable, improving, worsening, recurring, or limiting normal activity?

✓

Can I keep fluids and food down, how often am I urinating, and do I have repeated vomiting, diarrhea, constipation, dizziness, fainting, fever, jaundice, or severe abdominal pain?

✓

Are there vision changes, low-blood-sugar symptoms, facial or throat swelling, trouble breathing, widespread hives, a neck mass, persistent hoarseness, or swallowing difficulty?

✓

Did symptoms follow a clinician-directed treatment change, refill, storage problem, illness, procedure, travel, diet change, alcohol use, or another medicine?

✓

Do insulin, sulfonylureas, kidney disease, diabetic retinopathy, severe stomach-emptying symptoms, gallbladder history, pregnancy plans, or an upcoming procedure change the plan?

✓

Should the current package, prescription, refill or lot, storage history, inactive ingredients, injection supplies, or dispensing source be reviewed?

✓

Who should decide whether treatment pauses, continues, or changes, and which symptoms require same-day, urgent, or emergency care?

FAQs

Short answers for patients

What are the most common side effects of Wegovy injection?

Current adult Wegovy injection labeling lists nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, indigestion, dizziness, bloating, burping, low blood sugar in a defined type 2 diabetes subgroup, gas, gastroenteritis, reflux, gastritis, hair loss, and altered-sensation symptoms among reactions reported in at least 2% and more often than with placebo.

How common is nausea with Wegovy injection?

In pooled adult weight-reduction trials of the branded 2.4 mg once-weekly injection, nausea occurred in 44% of Wegovy participants versus 16% receiving placebo. This study-group comparison is not an individual prediction and should not be transferred to Wegovy tablets or another semaglutide product.

How long do Wegovy injection side effects last?

The current label does not provide one duration that applies to every reaction or patient. Persistent, recurrent, worsening, severe, or intake-limiting symptoms should be reported to the prescriber rather than managed with a universal waiting period.

Do Wegovy injection rates apply to Wegovy tablets?

No. The percentages on this page come from pooled adult trials of the branded 2.4 mg weekly injection. The current label also includes once-daily Wegovy tablets, but injection percentages should not be presented as exact tablet rates.

Are injection-site reactions the same as whole-product side effects?

No. This page provides a whole-product injection safety overview. The label separately reports a grouped local-reaction category, and the Wegovy injection-site-reaction guide covers that intent in detail. Systemic allergy symptoms or worsening local symptoms need prompt assessment.

Do Wegovy injection rates apply to compounded semaglutide?

No. A patient-specific compounded preparation is not FDA-approved Wegovy and may differ in concentration, inactive ingredients, presentation, supplies, labeling, storage, and beyond-use date. Wegovy trial percentages do not establish its side-effect incidence or quality.

Should I stop Wegovy because of side effects?

Do not skip, repeat, stop, restart, split, increase, decrease, or switch treatment based on generic online advice. Contact the responsible prescriber with the exact product and symptom pattern before the next treatment decision. Serious warning signs require prompt in-person or emergency assessment.

When are Wegovy injection side effects urgent?

Seek prompt care for severe or persistent abdominal pain, repeated vomiting, inability to keep fluids down, markedly reduced urination, fainting, confusion, jaundice, sudden vision change, trouble breathing or swallowing, facial or throat swelling, widespread hives, a neck mass with swallowing difficulty, or rapidly worsening symptoms.

Sources and related reading

Peptide12 pages use conservative educational language and authoritative sources where possible.

DailyMed: Current WEGOVY injection and tablet prescribing information — updated June 18, 2026 DailyMed API: Manufacturer WEGOVY structured product label MedlinePlus: Semaglutide injection drug information — revised May 15, 2026 MedlinePlus: Dehydration MedlinePlus: Low blood sugar FDA: Compounding and the FDA — Questions and Answers Peptide12: Wegovy Peptide12: Compounded semaglutide injection Peptide12: Wegovy injection-site reaction Peptide12: Wegovy injection sites Peptide12: Oral Wegovy side effects Peptide12: Semaglutide nausea Peptide12: GLP-1 low blood sugar Peptide12: When to message your clinician Peptide12: How online peptide therapy works